Pinnacle Financial Partners Inc Has $476,000 Stake in Novartis AG (NYSE:NVS)

Pinnacle Financial Partners Inc lifted its position in shares of Novartis AG (NYSE:NVS) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,823 shares of the company’s stock after purchasing an additional 198 shares during the period. Pinnacle Financial Partners Inc’s holdings in Novartis were worth $476,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Centaurus Financial Inc. lifted its holdings in Novartis by 1.7% during the 3rd quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after buying an additional 98 shares during the period. Clear Harbor Asset Management LLC lifted its holdings in Novartis by 2.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock worth $509,000 after buying an additional 100 shares during the period. Allen Wealth Management LLC lifted its holdings in Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after buying an additional 100 shares during the period. WealthPlan Investment Management LLC lifted its holdings in Novartis by 1.1% during the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company’s stock worth $1,092,000 after buying an additional 100 shares during the period. Finally, Avidian Wealth Enterprises LLC lifted its holdings in Novartis by 1.3% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 7,913 shares of the company’s stock worth $910,000 after buying an additional 102 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Up 2.0 %

NVS stock opened at $109.42 on Monday. The stock’s 50 day simple moving average is $101.46 and its 200 day simple moving average is $108.11. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The company has a market cap of $223.65 billion, a P/E ratio of 18.61, a price-to-earnings-growth ratio of 1.70 and a beta of 0.58.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, research analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

NVS has been the topic of several recent research reports. Barclays reaffirmed an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. UBS Group restated a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Erste Group Bank restated a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Finally, BMO Capital Markets upped their target price on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novartis has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.